Cargando…

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer

BACKGROUND: Prostate cancer (PCa) tumors harboring translocations of ETS family genes with the androgen responsive TMPRSS2 gene (ETS+ tumors) provide a robust biomarker for detecting PCa in approximately 70% of patients. ETS+ PCa express high levels of the androgen receptor (AR), yet PCa tumors lack...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berglund, Anders E., Rounbehler, Robert J., Gerke, Travis, Awasthi, Shivanshu, Cheng, Chia-Ho, Takhar, Mandeep, Davicioni, Elai, Alshalalfa, Mohammed, Erho, Nicholas, Klein, Eric A., Freedland, Stephen J., Ross, Ashley E., Schaeffer, Edward M., Trock, Bruce J., Den, Robert B., Cleveland, John L., Park, Jong Y., Dhillon, Jasreman, Yamoah, Kosj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760558/ https://www.ncbi.nlm.nih.gov/pubmed/30367117 http://dx.doi.org/10.1038/s41391-018-0103-4

Ejemplares similares

ANPEP: A Potential Regulator of Tumor Cell—Immune Metabolic Interactions in Prostate Cancer of Men of African Descent
por: Elkenawi, Asmaa, et al.
Publicado: (2022)

RF05 | PSUN358 ANPEP: A potential regulator of tumor cell - macrophage metabolic interactions in prostate cancer of African American men
por: Yamoah, Kosj, et al.
Publicado: (2022)

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

Evolving transcriptomic fingerprint based on genome‐wide data as prognostic tools in prostate cancer
por: Alshalalfa, Mohammed, et al.
Publicado: (2015)

Development of a predictive model for stromal content in prostate cancer samples to improve signature performance
por: Boufaied, Nadia, et al.
Publicado: (2019)

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma
por: Tsai, Harrison K., et al.
Publicado: (2017)

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
por: Liu, Deli, et al.
Publicado: (2018)

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma
por: Alshalalfa, Mohammed, et al.
Publicado: (2019)

African‐American men and prostate cancer‐specific mortality: a competing risk analysis of a large institutional cohort, 1989–2015
por: Williams, Vonetta L., et al.
Publicado: (2018)

Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study
por: Awasthi, Shivanshu, et al.
Publicado: (2019)

Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
por: Asamoah, Francis A., et al.
Publicado: (2019)

Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer
por: Erho, Nicholas, et al.
Publicado: (2012)

Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies
por: Stoyanova, Radka, et al.
Publicado: (2016)

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
por: Alshalalfa, Mohammed, et al.
Publicado: (2017)

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
por: Kim, Hyun, et al.
Publicado: (2016)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
por: Rayford, Walter, et al.
Publicado: (2021)

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
por: Yang, Lingjian, et al.
Publicado: (2018)

Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
por: Ayettey Anie, Hannah, et al.
Publicado: (2021)

Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer
por: Mitra, Anirban P., et al.
Publicado: (2014)

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
por: Ramnarine, Varune Rohan, et al.
Publicado: (2018)

Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
por: Vergara, Ismael A., et al.
Publicado: (2012)

KLK3 SNP–SNP interactions for prediction of prostate cancer aggressiveness
por: Lin, Hui-Yi, et al.
Publicado: (2021)

CREB Targets Define the Gene Expression Signature of Malignancies Having Reduced Levels of the Tumor Suppressor Tristetraprolin
por: Fallahi, Mohammad, et al.
Publicado: (2014)

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
por: Labbé, David P., et al.
Publicado: (2019)

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies
por: Jäger, Wolfgang, et al.
Publicado: (2015)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1
por: Spans, Lien, et al.
Publicado: (2016)

Proton beam therapy: clinical utility and current status in prostate cancer
por: Yamoah, Kosj, et al.
Publicado: (2016)

Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function
por: Berglund, Anders E., et al.
Publicado: (2016)

Lipid degradation promotes prostate cancer cell survival
por: Itkonen, Harri M, et al.
Publicado: (2017)

Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis
por: Lee, Hak J, et al.
Publicado: (2016)

Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience
por: Asamoah, Francis A., et al.
Publicado: (2018)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

miRNAs associated with prostate cancer risk and progression
por: Luu, Hung N., et al.
Publicado: (2017)

Androgen deprivation therapy and side effects: are GnRH antagonists safer?
por: Freedland, Stephen J, et al.
Publicado: (2020)

Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy
por: Faraj, Sheila F., et al.
Publicado: (2016)

The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
por: Prensner, John R., et al.
Publicado: (2014)

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance
por: Nouri, Mannan, et al.
Publicado: (2017)

Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men
por: Berglund, Anders, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v2ngn9a30o5kl93840daam5dse